SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy

SOTIO Completes Enrollment for Phase 3 Trial of DCVAC/PCa Immunotherapy
The Phase 3 trial evaluating the immunotherapy DCVAC/PCa in men with metastatic castration-resistant prostate cancer (mCRPC), has completed patient enrollment, according to trial sponsor, SOTIO. The treatment is being evaluated as an add-on to standard of care chemotherapy – Taxotere (docetaxel) – for patients who have not received prior chemotherapy. “The completion of the patient enrolment to the VIABLE study is an important milestone. It is a major step towards registration of our active cellular immunotherapy and making it available for routine clinical use," Ladislav Bartonicek, CEO of SOTIO, said in a press release. "We are grateful to all our medical partners, the patients and their families for their ongoing support of this study. After finalization of treatment and follow-up period we expect to finalize the primary analysis of the data in 2020.” SOTIO has been developing a new immunotherapy strategy based on the activation of a specific subset of immune cells, called dendritic cells, to boost anti-tumor immune responses. Dendritic cells are responsible for pointing out to T-cells elements that should recognized as harmful, such as cancer proteins. SOTIO’s strategy is to take advantage of the natural activity of dendritic cells and expose them to cancer-specific antigens. This process optimizes the activation of T-cells toward  cancer cells. SOTIO's approach consists of collecting a patient's own dendritic cells, which are then activated in the company's laboratories by exposure to dead cancer cells. In addition to DCVAC/PCa, SOTIO is developing two other
Subscribe or to access all post and page content.